A candidate treatment for patients with glaucoma, Vesneo, has reached its primary endpoint in a Phase 3 development programme, showing that it can effectively lower intraocular pressure, according to Nicox SA, the developer.
Antibiotic drug development has received a boost with the decision by a syndicate of Scottish investors to support MGB Biopharma Ltd, which has an agent to treat Gram-positive infections in development. The drug is set to enter the clinic in the first half of 2015.
A Phase 3 study of a new drug regime for tuberculosis, which involved replacing the antibiotic moxifloxacin for one of two other drugs, failed to shorten the treatment time for the disease from six to four months. But the new regime was safe, according to the Global Alliance for TB Drug Development.
Real world data from an experimental vaccine for birch pollen allergy, AllerT, have shown statistically significant reductions in seasonal allergy symptoms, as well as an effect into a second pollen season, according to the developer, Anergis SA.
Merck KGaA of Germany has decided to discontinue the clinical development of the immunotherapy tecemotide in non-small cell lung cancer following the failure of a Japanese study to show effectiveness on any trial endpoint.
Eli Lilly and Company said the results of a Phase 3 study of its antibody treatment Cyramza (ramucirumab), which has already been approved for advanced gastric cancer, met its primary endpoint of overall survival in patients with metastatic colorectal cancer.
Data from two Phase 3 studies of the antibody mepolizumab in severe asthma have shown statistically significant reductions in asthma exacerbations and a reduction in the need for daily oral corticosteroid use, according to the developer, GlaxoSmithKline Plc.
Alizé Pharma SAS has raised €5 million to finance further development of an analog of a metabolic hormone that has the potential to treat type-2 diabetes and a rare children’s disease called the Prader-Willi syndrome.
Results of a Phase 2 study of benralizumab from AstraZeneca Plc for chronic obstructive pulmonary disease (COPD) have been published in The Lancet Respiratory Medicine. The drug is said to be the first biologic to show a marked reduction in inflammation.
Novartis is planning regulatory submissions in both the US and Europe for a new heart drug in the wake of trial results showing the drug's superior performance to enalapril, a standard treatment for hypertension and heart failure.